Wells Fargo analyst Derek Archila raised the firm’s price target on Morphic to $80 from $67 and keeps an Overweight rating on the shares after the company reports results from the EMERALD-1 Phase 2a study of MORF-057 in adults with moderate to severe ulcerative colitis, or UC. The firm sees higher odds of success in UC and Crohn’s disease, or CD, following what it views as "positive" data, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MORF:
- MORF Jumps after Positive Clinical Data
- Morphic reports results from EMERALD-1 Phase 2a study of MORF-057
- Morphic reports Q1 EPS (90c), consensus (80c)
- Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2023
- Morphic Therapeutic to Host EMERALD-1 Topline Results Call on April 25, 2023